Fairmount Partners Advises FutureMeds, Europe's Leading Clinical Trial Site Network, on Investment from Phoenix Equity Partners
- Fairmount Partners
- Jul 28, 2025
- 3 min read
LONDON, UK – July 29th, 2025 – Phoenix Equity Partners (“Phoenix”), the UK private equity firm, focused on partnering with founder-entrepreneurs, is pleased to announce its latest investment in FutureMeds, a group of research sites providing patient recruitment and clinical trial management services across Europe.
Phoenix is proud to be partnering with FutureMeds’ three co-founders; Dr Radoslaw Janiak (CEO), Marcin Gondek (CFO) and Paul Chambers (Chair). Having started the business in 2020, they have grown FutureMeds quickly to be the leading site management organization (SMO) across Europe. The company provides end-to-end clinical trial services, including patient recruitment, clinical trial execution and hybrid/virtual trial services for major global pharma sponsors and Contract Research Organizations (CROs). Today, the business operates 27 clinical sites across 7 European countries with hybrid/virtual solutions in 18 different countries. Phoenix will support FutureMeds through its next stage of growth, as it continues to deliver high-quality clinical trials, contributing to the development of innovative new therapies.
Phoenix’s investment strategy focuses on founder-led businesses in high-growth niches where it has deep expertise. This investment in FutureMeds marks the tenth from Phoenix’s current fund and builds on the firm’s strong track record in Outsourced Pharma Services, exemplified by its former successful partnership with Sygnature Discovery, a leading provider of integrated drug discovery services. Over the past three years, Phoenix has built a strong relationship with the FutureMeds team, and the investment reflects both confidence in the management team and conviction in the opportunity ahead.
FutureMeds is already Europe’s largest independent SMO network, and with Phoenix as its partner, it is well-positioned to accelerate its growth. The business will expand its geographic footprint, increase patient recruitment, deliver a greater volume of trials, and deepen its expertise across a broader range of therapeutic areas. By doing so, FutureMeds aims to help bring new therapies to market more quickly and support a growing base of global pharma sponsors and CROs.
Fairmount Partners acted as exclusive financial advisor to FutureMeds. This project is the 190th pharma services transaction for Fairmount, and the 11th project focused on clinical research sites and patient recruitment.
“Our success to date has been driven by the exceptional people across FutureMeds who bring deep commitment, clinical expertise and a shared culture focused on excellence. We are proud of what we have built together and believe Phoenix is the right partner to support us in the next phase of our journey.”
Paul Chambers, Co-Founder & Chair, FutureMeds, commented:
“We have grown FutureMeds into the largest SMO network in Europe, but we are still just scratching the surface of what is possible. The opportunity ahead to expand our reach, broaden our capabilities and serve even more patients and sponsors is enormous. We see our partnership with Phoenix as an important step in unlocking the next phase of scale and ambition.”
Kevin Keck, Managing Partner, Phoenix Equity Partners, commented:
“We have known Radek, Marcin and Paul for several years and have been consistently impressed by the vision, dedication and quality of the team they have built”
Barry Robinson, Partner, Phoenix Equity Partners, added:
“Our investment reflects Phoenix’s continued commitment to partnering with founder-led businesses in sectors where we have deep research and conviction. We’re really looking forward to the journey ahead.”
About Phoenix Equity Partners
Phoenix Equity Partners is a leading private equity firm that supports founder-entrepreneur-owned businesses in the UK. With over two decades of experience and more than 60 successful founder partnerships, Phoenix is committed to nurturing founders, their teams, and the entrepreneurial cultures they have built. For more information, visit www.phoenix-equity.com.
About Fairmount Partners
Fairmount Partners is an independent investment banking firm focused on supporting middle-market companies to complete mergers and acquisitions, raise funds for growth, acquisitions and liquidity, and design and improve their corporate development strategies. Fairmount’s clients include successful entrepreneurs, private equity-sponsored enterprises, and global public companies. Since 2003, Fairmount has completed more than 310 transactions representing over $17 billion in aggregate value across 25 countries throughout North and South America, Asia, Australia, Europe, and the Middle East. For additional information, please visit www.fairmountpartners.com.
Contacts
Neal McCarthy
Managing Director, Fairmount Partners
Cecilia Gleason, PhD
Director, Fairmount Partners